瑞舒伐他汀、辛伐他汀治疗高脂血症伴发冠心病疗效对比观察

被引：30

作者：

徐惠

崔飞飞

机构：

[1] 东台市中医院

来源：

山东医药 | 2013年 / 53卷 / 48期

关键词：

冠状动脉硬化性心脏病; 高脂血症; 瑞舒伐他汀; 辛伐他汀;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

100201 [内科学];

摘要：

目的对比观察瑞舒伐他汀、辛伐他汀治疗高血脂症伴发冠心病(CHD)的效果。方法将142例高脂血症伴CHD患者随机分为观察组85例和对照组57例,在常规治疗基础上分别每晚口服瑞舒伐他汀、辛伐他汀10mg,治疗2个月。治疗前后检测两组血清TG、TC、LDL-C、HDL-C、hs-CRP、载脂蛋白A1(Apo A1)、载脂蛋白B(Apo B)、ALT、BUN、Cr、肌酸磷酸激酶(CK)等指标。结果两组治疗后血清TG、TC、LDL-C、hs-CRP、Apo A1、Apo B均明显降低(P均<0.05),HDL-C均明显升高(P均<0.05);与对照组比较,观察组降低幅度更加明显(P均<0.05);两组治疗后ALT、BUN、Cr、CK升高幅度并不明显,差异无统计学意义(P均>0.05)。结论瑞舒伐他汀降脂、抗炎效果优于辛伐他汀,且安全性良好。

引用

页码：38 / 40

页数：3

共 11 条

[1]

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies [J].

Roth, Eli M. ;

Rosenson, Robert S. ;

Jones, Peter H. ;

Davidson, Michael H. ;

Kelly, Maureen T. ;

Setze, Carolyn M. ;

Lele, Aditya ;

Thakker, Kamlesh .

JOURNAL OF CLINICAL LIPIDOLOGY, 2012, 6 (06) :534-544

[2]

Change in near-infrared spectroscopy of a coronary artery after 1-year treatment with high dose rosuvastatin.[J].C. Simsek;R.J. van Geuns;M. Magro;E. Boersma;H.M. Garcia-Garcia;P.W. Serruys.International Journal of Cardiology.2011, 3

[3]

The Cost-Effectiveness of Rosuvastatin Therapy.[J].Mark Hlatky.Journal of the American College of Cardiology.2011, 7

[4]

Primary prevention of coronary heart disease: integration of new data; evolving views; revised goals; and role of rosuvastatin in management. A comprehensive survey.[J].Richard Kones.Drug Design; Development and Therapy.2011, defa

[5]

Beyond coronary artery disease: Rosuvastatin in older patients with ischemic systolic heart failure [J].

Capurso, Cristiano ;

Solfrizzi, Vincenzo ;

D'Introno, Alessia ;

Colacicco, Anna M. ;

Gadaleta, Annamaria ;

Frisardi, Vincenza ;

Santamato, Andrea ;

Capurso, Antonio ;

Panza, Francesco .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (07) :1366-1367

[6]

Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: Comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial [J].

Insull, William, Jr. ;

Ghali, Jalal K. ;

Hassman, David R. ;

Ycas, Joseph W. ;

Gandhi, Sanjay K. ;

Miller, Elinor .

MAYO CLINIC PROCEEDINGS, 2007, 82 (05) :543-550

[7]

Guidelines for Lowering Lipids to Reduce Coronary Artery Disease Risk: A Comparison of Rosuvastatin with Atorvastatin; Pravastatin; and Simvastatin for Achieving Lipid-Lowering Goals.[J].James Shepherd;Donald B. Hunninghake;Philip Barter;James M. McKenney;Howard G. Hutchinson.Atherosclerosis (Supplements) (Component).2004, 3

[8]

Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY study [J].

Strandberg, TE ;

Feely, J ;

Sigurdsson, EL .

CLINICAL THERAPEUTICS, 2004, 26 (11) :1821-1833

[9]

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.[J].James W Blasetto;Evan A Stein;W.Virgil Brown;Rohini Chitra;Ali Raza.The American Journal of Cardiology.2003, 5

[10]

Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin 1 1 CRESTOR is a trademark; the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca..[J].Anders G Olsson.The American Journal of Cardiology.2001, 5

← 1 2 →